The Astounding Account of the IL-17 and Spondylarthritis

In this episode, we focus on the history of researchers discovering the clinical applicability of the IL 23/17 axis, with a particular emphasis on psoriasis, psoriatic arthritis and axial SpA

 

·        Intro 0:01

·        In this episode 0:12

·        Leonard Calabrese, DO, is listening! 0:54

·        Recap of last episode 3:09

·        Putting the pieces together 5:12

·        Quick overview of this science heavy episode 6:11

·        What is psoriasis? 7:26

·        Immunosuppressants for psoriasis/ Throwing meds at people and seeing what happens 10:10

·        In the modern world of 1986 – olive oil placebo trial 11:36

·        A quick aside into fungi 12:35

·        What kind of T-cells are involved here? 16:41

·        The TH-1 hypothesis 18:20

·        IL-23 and IL-17 are doing something 19:34

·        Going back to the drawing board in 2004 20:00

·        p40 + p19 = IL-23 21:00

·        IL-23 via minicircle DNA in mice 23:05

·        Brand new and shiny TH-17 25:23

·        The family of IL-17 26:36

·        What do we know about IL-17 and psoriasis? 27:10

·        IL-17A vs IL-17F in mouse studies 27:35

·        Finding the difference between IL-17A and IL-17F in humans 28:23

·        What exactly is IL-17 doing? 29:30

·        The articular manifestations of psoriatic arthritis 30:57

·        Spondylarthritis and the IL 23/17 axis 33:56

·        T-cells we haven’t talked about 35:40

·        Summary of this episode 39:08

·        Thanks for listening 41:34

 

We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum.

References:

Bashyam H. J Exp Med. 2007;doi:10.1084/jem.2042fta

Bjerke R J. Acta Derm Venereol. 1982;PMID:6179355

Cargill M, et al. Am J Hum Genet. 2007;doi:10.1086/511051

Chan J R, et al. J Exp Med. 2006;doi:10.1084/jem.20060244

Cuthbert R J, et al. Ann Rheum Dis. 2019;doi:10.1136/annrheumdis-2019-215210

Ellis C N, et al. JAMA. 1986;doi:10.1001/jama.1986​

Ettehadi P, et al. Clin Exp Immunol. 1994;doi:10.1111/j.1365-2249.1994.tb06244.x

Furue M, et al. Int J Mol Sci. 2020;doi:10.3390/ijms21041275

Gooderham M J, et al. J Eur Acad Dermatol Venereol. 2018;doi:10.1111/jdv.14868

Lee E, et al. J Exp Med. 2004;doi:10.1084/jem.20030451

Leonardi C L, et al. Lancet. 2008;doi:10.1016/S0140-6736(08)60725-4

Mease P J, et al. Lancet. 2000;doi:10.1016/S0140-6736(00)02530-7

Menon B, et al. Arthritis Rheumatol. 2014;doi:10.1002/art.38376

Moos S, et al. J Invest Dermatol. 2019;doi:10.1016/j.jid.2019.01.006

Muelle W, et al. N Engl J Med. 1979;doi:10.1056/NEJM197909063011016

Papp K A, et al. Lancet. 2008;doi:10.1016/S0140-6736(08)60726-6

Reinhardt A, et al. Arthritis Rheumatol. 2016;doi:10.1002/art.39732

Sherlock J P, et al. Nat Med. 2012;doi:10.1038/nm.2817

Tribe H T. Mycologist. 1998;doi:10.1016/S0269-915X(98)80100-6

Yawalkar N, et al. J Invest Dermatol. 1998;doi:10.1046/j.1523-1747.1998.00446.x

Zaba L C, et al. J Allergy Clin Immunol. 2009;doi:10.1016/j.jaci.2009.08.046

 

Disclosures: Brown reports no relevant financial disclosures.